NASDAQ:ITCI • US46116X1019
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INTRA-CELLULAR THERAPIES INC (ITCI).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-04-02 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2025-02-24 | Mizuho | Downgrade | Outperform -> Neutral |
| 2025-02-21 | Needham | Reiterate | Hold -> Hold |
| 2025-01-31 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2025-01-22 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2025-01-14 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2025-01-13 | Needham | Downgrade | Buy -> Hold |
| 2024-11-04 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-10-31 | Needham | Reiterate | Buy -> Buy |
| 2024-10-30 | Needham | Reiterate | Buy -> Buy |
| 2024-10-11 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-10-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-09-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-06 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2024-08-21 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-08-08 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-08-08 | UBS | Maintains | Neutral -> Neutral |
| 2024-08-08 | Needham | Reiterate | Buy -> Buy |
| 2024-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-08-08 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-08-07 | Needham | Reiterate | Buy -> Buy |
| 2024-07-22 | Needham | Maintains | Buy -> Buy |
| 2024-06-25 | UBS | Downgrade | Buy -> Neutral |
| 2024-06-25 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 250.3M 198.69% | 464.37M 85.53% | 680.852M 46.62% | 966.26M 41.92% | 1.566B 62.07% | 2.215B 41.44% | 2.757B 24.47% | 3.385B 22.78% | 3.525B 4.14% | 3.797B 7.72% | 4.056B 6.82% | |
| EBITDA YoY % growth | -262.94M 7.80% | -158.853M 39.59% | -116.213M 26.84% | 29.026M 124.98% | 491.43M 1,593.07% | 1.174B 138.89% | 1.85B 57.58% | 2.487B 34.43% | 2.83B 13.79% | 3.07B 8.48% | 3.279B 6.81% | |
| EBIT YoY % growth | -263.6M 7.74% | -159.381M 39.54% | -116.721M 26.77% | -11.62M 90.04% | 442.48M 3,907.87% | 1.066B 140.91% | 1.669B 56.57% | 2.166B 29.78% | 2.274B 4.99% | 2.721B 19.66% | 2.883B 5.95% | |
| Operating Margin | -105.31% | -34.32% | -17.14% | -1.20% | 28.26% | 48.13% | 60.54% | 63.99% | 64.51% | 71.66% | 71.08% | |
| EPS YoY % growth | -2.72 22.29% | -1.46 46.32% | -0.73 50.00% | 0.20 127.35% | 4.03 1,917.44% | 8.72 116.50% | 10.81 24.01% | 15.25 41.06% | 15.57 2.06% | 16.79 7.86% | 17.66 5.16% |
All data in USD
| Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.11 33.06% | -0.03 81.94% | 0.02 109.79% | 0.20 227.50% |
| Revenue Q2Q % growth | 210.57M 45.36% | 226.45M 40.31% | 243.42M 38.80% | 279.79M 40.44% |
| EBITDA Q2Q % growth | -12.985M 37.63% | -4.57M 83.36% | -9.353M 75.67% | -12.138M 57.69% |
| EBIT Q2Q % growth | -19.846M 5.28% | -12.401M 55.27% | -496.23K 98.72% | 20.925M 171.67% |
All data in USD
18 analysts have analysed ITCI and the average price target is 133.21 USD. This implies a price increase of 1.02% is expected in the next year compared to the current price of 131.87.
INTRA-CELLULAR THERAPIES INC (ITCI) will report earnings on 2025-05-05, before the market open.
The consensus EPS estimate for the next earnings of INTRA-CELLULAR THERAPIES INC (ITCI) is -0.11 USD and the consensus revenue estimate is 210.57M USD.
The number of analysts covering INTRA-CELLULAR THERAPIES INC (ITCI) is 18.